Researchers have identified an unconventional way to kill pancreatic cancer cells, one that works by flooding their survival pathways with too much of a good thing. Instead of blocking the signals that fuel tumor growth, an experimental compound hyperactivates them to the point of cellular collapse.
The work, published in Oncotarget and led by scientists at Florida A&M University, examined a class of drugs called polyisoprenylated cysteinyl amide inhibitors, or PCAIs. The compounds target pancreatic cancers driven by mutations in the KRAS gene, a major reason pancreatic tumors are so hard to treat and so often lethal.
Pancreatic ductal adenocarcinoma ranks among the deadliest human malignancies. KRAS mutations appear in the majority of cases, fueling tumor growth and resistance to therapy. While newer drugs can target certain KRAS variants, many patients still have no effective options. The new findings suggest a fundamentally different approach could expand the arsenal.
The research team tested PCAIs on pancreatic cancer cells and observed striking results. One compound in particular, NSL-YHJ-2-27, decimated the cancer cells' ability to move and spread. At just one micromolar concentration, it blocked more than 90 percent of cell migration, a critical step in metastasis. The compound also reduced the viability of the cancer cells themselves.
When researchers examined the mechanism, they found something unexpected. The PCAIs didn't suppress the two major signaling pathways linked to cancer growth, called MAPK and PI3K/AKT. Instead, they cranked them up to extreme levels.
This hyperactivation proved lethal to the tumors. Overtaxed cells produced dangerous quantities of reactive oxygen species, activated enzymes that trigger programmed death, and unleashed waves of apoptosis. The cancer cells essentially poisoned themselves on their own growth signals.
The compound also disrupted the physical infrastructure cancer cells depend on. Levels of proteins involved in cell movement plummeted. The actin cytoskeleton, which gives cells their shape and mobility, fell apart. Treated cancer cells became rounded and immobilized.
Gene expression tests showed widespread shifts in cellular activity. Tumor-suppressing genes switched on while metastasis-promoting genes switched off. When researchers moved to more realistic three-dimensional tumor models that better approximate actual cancers, the PCAIs still worked. Tumor spheroids fragmented, lost their invasive capacity, and filled with dying cells.
The breadth of the approach may prove significant. Unlike some newer KRAS-targeted drugs that only work against specific mutations, PCAIs appear effective against multiple KRAS variants. That versatility could help patients whose tumors carry different genetic subtypes.
The findings do not yet translate to human patients. The work remains in the laboratory stage, using cell cultures and early tumor models. But the results are compelling enough to warrant further development as a potential treatment for pancreatic cancer and other KRAS-driven malignancies.
Author Jessica Williams: "Turning a cancer cell's own growth machinery against it is an elegant strategy, and these early results suggest PCAIs could hit a much broader range of tumors than current KRAS drugs can reach."
Comments